March 7, 2022
Fierce Medtech names Cleerly one of its "Fierce 15" Med Tech Companies of 2021
Cleerly today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 Med Tech Companies — recognizing venture-backed competitive companies championing innovation and creativity.
February 9, 2022
Cleerly Takes Precision Heart Care to the Next Level With Cleerly 2.2.0
Cleerly, the company creating a new standard of care for heart disease, announced its latest product release, Cleerly 2.2.0, that includes user experience (UX) refinements and three new high-value tools.
February 2, 2022
Cleerly Named to NYC Digital Health 100 by New York City Health Business Leaders
New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York’s healthcare ecosystem, has recognized Cleerly on its NYC Digital Health 100, showcasing the most exciting and innovative health start-ups in New York.
December 8, 2021
Cleerly Named to the 2021 CB Insights Digital Health 150
CB Insights today named Cleerly to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.
November 9, 2021
Cleerly Expands Board of Directors with Three New Members
Kevin M. King, Glenn D. Steele Jr., MD, PhD and Roy Beveridge, MD have joined the board to advise the company as it works to identify individuals at the earliest stage to prevent heart attacks and save lives with its digital care pathway solution.
October 18, 2021
Cleerly Appoints Jim Hartman as Chief Revenue Officer
Sales strategy expert brings industry success to leverage growth.
September 29, 2021
Cleerly Expands Executive Team with Appointment of New Chief Operating Officer and Chief Technology Officer
Brandon Atkinson joins as COO and Nick Nieslanik as CTO to Support Company’s Mission to Create a New Standard of Care for Heart Disease, the Leading Cause of Death.
June 21, 2021
Cleerly Launches with $43 Million Series B to Provide a New Standard of Care for the Leading Cause of Death – Heart Disease
Resulting from More than a Decade of Clinical Research, Company Unveils Non-Invasive Approach to Identify, and New Care Pathways to Address Heart Disease Using Artificial Intelligence.
Stay Up-to-Date with Cleerly
Let's connect! Sign up to receive the latest Cleerly news, product information, and upcoming event.
